Zhitong Finance App News, Changchun Hi-Tech (000661.SZ) issued an announcement. Recently, Changchun Jinsai Pharmaceutical Co., Ltd. (“Jinsai Pharmaceutical”), a holding subsidiary of the company, received the “Notice of Acceptance” approved and issued by the National Drug Administration (NMPA). Jinsai Pharmaceutical's application for registration of domestically produced drugs for GenSci 155 injection was accepted. GenSci 155 injection is a long-acting fatty acid-conjugated recombinant human insulin-like growth factor-1 (IGF-1) analog independently developed by Jinsai Pharmaceutical. It is registered as a class 1 therapeutic biological product. It is intended for use in the treatment of cerebral hemorrhage (specifically, spontaneous cerebral hemorrhage). The route of administration is intravenous injection.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.